Table 1.
Baseline Characteristics by Quartiles of Fibroblast Growth Factor-23. The Cardiovascular Health Study
| Range (RU/ml) | Fibroblast Growth Factor-23 Quartiles
|
|||
|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |
| < 51 | 51–70 | 71–100 | > 100 | |
| Number of Participants | 792 | 785 | 774 | 756 |
| Demographics | ||||
| Age (years) ± SD | 77 ± 5 | 77 ± 5 | 78 ± 5 | 79 ± 5 |
| Female n(%) | 421 (53%) | 444 (57%) | 491 (63%) | 503 (67%) |
| Black race n(%) | 180 (23%) | 115 (15%) | 96 (12%) | 106 (14%) |
| Self reported health fair or poor n(%) | 137 (17%) | 152 (19%) | 139 (18%) | 266 (35%) |
| Prevalent HF and CVD | ||||
| History of HF n(%) | 25 (3%) | 41 (5%) | 55 (7%) | 150 (20%) |
| History of MI n(%) | 60 (8%) | 59 (8%) | 93 (12%) | 127 (17%) |
| History of Stroke n(%) | 42 (5%) | 52 (7%) | 38 (5%) | 58 (8%) |
| History of Claudication n(%) | 16 (2%) | 16 (2%) | 27 (4%) | 39 (5%) |
| CVD Risk Factors | ||||
| Hypertension n(%) | 457 (58%) | 482 (61%) | 492 (64%) | 523 (69%) |
| Glycemia Status n(%) | ||||
| Impaired Fasting Glucose | 38 (5%) | 51 (7%) | 66 (9%) | 60 (8%) |
| Diabetes | 81 (10%) | 103 (13%) | 114 (15%) | 155 (21%) |
| Current smoker n(%) | 42 (5%) | 46 (6%) | 77 (10%) | 75 (10%) |
| Body mass index (kg/m2) ± SD | 26.3 ± 4.3 | 26.7 ± 4.2 | 27.3 ± 4.6 | 27.5 ± 5.3 |
| Total cholesterol (mg/dl) ± SD | 200 ± 37 | 202 ± 38 | 204 ± 41 | 203 ± 42 |
| Lipid lowering medication n(%) | 72 (9%) | 80 (10%) | 106 (14%) | 106 (14%) |
| C-reactive protein (mg/L), median [IQR] | 1.83 [0.91, 3.89] | 2.19 [0.99, 4.64] | 2.85 [1.28, 5.64] | 3.12 [1.50, 6.79] |
| Kidney Function | ||||
| eGFR (ml/min/1.73m2) ± SD | 81 ± 18 | 74 ± 17 | 69 ± 16 | 58 ± 19 |
| Urine ACR (mg/g), median (IQR) | 6.86 [4.28, 14.33] | 8.37 [4.50, 17.51] | 8.34 [4.71, 18.97] | 13.36 [6.01, 54.41] |
Abbreviations: HF=heart failure; CVD=cardiovascular disease; MI=myocardial infarction; eGFR=estimated glomerular filtration rate; ACR=albumin to creatinine ratio.